Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.
about
Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor InvasionMutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.MUC16 (CA125): tumor biomarker to cancer therapy, a work in progressDual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents.Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.Transmembrane mucins as novel therapeutic targetsUnderstanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy.Adoptive T-Cell Therapy for Solid Tumors.Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments.Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth.Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1.
P2860
Q27307193-3488CB3F-1FDA-40D2-B2BB-95A9C9ABC9AEQ27333756-3F4D5EF4-F100-4026-9E40-DADCAD889AF4Q33713506-D4E22B99-E98C-463E-ACF9-27436FB4822BQ33982446-15EBD4DC-8275-4D75-AE80-08B8F163781FQ34007762-765870D2-B439-4A62-8FF6-178B0BD3E7DAQ35506724-272326A3-57BA-4404-8EEE-2AB179F1BAFAQ35591546-347E28A7-245A-450B-92AF-0A6C8C2BB06EQ35627284-BCCA8CEA-CB22-4AD8-A296-E81A81711296Q35632645-80975E2E-B615-411B-A978-01F2544368C4Q38623057-C49EF630-B332-4989-9CAD-3462208634D8Q38754498-4A8C5D94-2E76-4A01-B853-F8FD4F30C9FAQ41790227-ED94F585-6619-4911-9893-F136F9FF05BFQ46024099-B0A0D4F0-4CB4-49CD-B0AC-B21613C0497BQ46111623-48118CB4-B01E-45EA-BDF8-A56712190B53Q47096729-D19184C0-3DC7-43F9-81B9-CF69E3C79BC8
P2860
Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.
@ast
Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.
@en
type
label
Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.
@ast
Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.
@en
prefLabel
Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.
@ast
Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.
@en
P2093
P2860
P1476
Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16
@en
P2093
Alexia Iasonos
David R Spriggs
Irina Linkov
Peter Smith-Jones
Thapi Dharma Rao
P2860
P304
P356
10.1097/PAI.0B013E3181DBFCD2
P577
2010-10-01T00:00:00Z